Malishevskiĭ M V
Kardiologiia. 2012;52(11):66-74.
Irbesartan is a noncompetitive angiotensin II receptor type 1 antagonist which has been successfully used for more than 10 years for the treatment of hypertensive disease. In a dose of 150-300 mg/day irbesartan produces long term effect for 24 hours. Its antihypertensive efficacy is augmented by concomitant administration of hydrochlorothiazide. Irbesartan reduces left ventricular hypertrophy and increases probability of maintenance of sinus rhythm after cardioversion of atrial fibrillation. Renoprotective effects of irbesartan has been demonstrated both at early and late stages of kidney involvement in patients with type 2 diabetes. Therapeutic efficacy and safety of irbesartan ensure high level of patients compliance. Irbesartan as monotherapy or as combination with hydrochlorothiazide demonstrate contemporary therapeutic approach to arterial hypertension as well as to diabetic nephropathy both at its early and late stages.
厄贝沙坦是一种非竞争性的1型血管紧张素II受体拮抗剂，已成功用于治疗高血压疾病10多年。每日剂量为150 - 300毫克时，厄贝沙坦可产生长达24小时的长期疗效。同时服用氢氯噻嗪可增强其降压效果。厄贝沙坦可减轻左心室肥厚，并增加心房颤动复律后维持窦性心律的概率。在2型糖尿病患者肾脏受累的早期和晚期，均已证实厄贝沙坦具有肾脏保护作用。厄贝沙坦的治疗效果和安全性确保了患者的高依从性。厄贝沙坦单药治疗或与氢氯噻嗪联合使用，在动脉高血压以及糖尿病肾病的早期和晚期，均展现了当代的治疗方法。
